RT Journal Article
SR Electronic
T1 Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21256110
DO 10.1101/2021.04.26.21256110
A1 Osmanov, Ismail M
A1 Spiridonova, Ekaterina
A1 Bobkova, Polina
A1 Gamirova, Aysylu
A1 Shikhaleva, Anastasia
A1 Andreeva, Margarita
A1 Blyuss, Oleg
A1 El-Taravi, Yasmin
A1 DunnGalvin, Audrey
A1 Comberiati, Pasquale
A1 Peroni, Diego G
A1 Apfelbacher, Christian
A1 Genuneit, Jon
A1 Mazankova, Lyudmila
A1 Miroshina, Alexandra
A1 Chistyakova, Evgeniya
A1 Samitova, Elmira
A1 Borzakova, Svetlana
A1 Bondarenko, Elena
A1 Korsunskiy, Anatoliy A
A1 Konova, Irina
A1 Hanson, Sarah Wulf
A1 Carson, Gail
A1 Sigfrid, Louise
A1 Scott, Janet T
A1 Greenhawt, Matthew
A1 Whittaker, Elizabeth A
A1 Garralda, Elena
A1 Swann, Olivia
A1 Buonsenso, Danilo
A1 Nicholls, Dasha E
A1 Simpson, Frances
A1 Jones, Christina
A1 Semple, Malcolm G
A1 Warner, John O
A1 Vos, Theo
A1 Olliaro, Piero
A1 Munblit, Daniel
A1 Sechenov StopCOVID Research Team
YR 2021
UL http://medrxiv.org/content/early/2021/04/26/2021.04.26.21256110.abstract
AB Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors.Methods This is a prospective cohort study of children (≤18 years old) admitted with confirmed Covid-19 to Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Moscow, Russia. Children admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow up survey. Persistent symptoms (>5 months) were further categorised by system(s) involved.Findings Overall, 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3–15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: age “6-11 years” (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and “12-18 years” (2.68, 1.41 to 5.4), and a history of allergic diseases (1.67, 1.04 to 2.67).Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up. Our findings highlight the need for replication and further investigation of potential mechanisms as well as clinical support to improve long term outcomes in children.Funding None.Research in contextEvidence before this studyEvidence before this study Evidence suggests that Covid-19 may result in short- and long-term consequences to health. Studies in children and adolescents are limited and available evidence is scarce. We searched Embase for publications from inception to April, 25, 2021, using the following phrases or combinations of phrases “post-covid condition” or “post-covid syndrome” or “covid sequalae” or “post-acute covid” or “long covid” or “long hauler” with “pediatric*” or “paediatric*” or “child*” or “infant*” or “newborn*” or “toddler*” or “neonate*” or “neonatal” or “adolescent*” or “teen*”. We found small case series and small cohort studies looking at Covid-19 consequences in children. No large cohort studies of previously hospitalised children, assessing symptom duration, categorisation or attempting multivariable analyses to identify independent risk factors for long Covid development were identified.Added value of this studyAdded value of this study To our knowledge, this is the largest cohort study with the longest follow-up since hospital discharge of previously hospitalised children. We found that even months after discharge from the hospital, approximately a quarter of children experience persistent symptoms with one in ten having multi-system involvement. Older age and allergic diseases are associated with Covid-19 consequences. Parents of some children report emotional and behavioural changes in their children after Covid-19.Implications of all the available evidenceImplications of all the available evidence Our findings highlight the need for continued global research of Covid-19 consequences in the paediatric population. Older children admitted to the hospital should be carefully monitored upon discharge. Large, controlled studies aiming to identify risk groups and potential intervention strategies are required to fill knowledge gaps.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not have external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Moscow City Independent Ethics Committee (abbreviate 1, protocol number 74).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, DM, upon reasonable request.